The kidney cancer drugs market comprises drugs used for the treatment of kidney cancer also known as renal cell carcinoma (RCC). Renal cell carcinoma is one of the most common types of kidney cancers which starts in the lining of very small tubes (tubules) in the kidney. Some of the commonly used kidney cancer drugs include inhibitors for angiogenesis, mTOR inhibitors, and immune checkpoint inhibitors. Inhibitors for angiogenesis works by blocking the growth of new blood vessels that tumors need to grow which include drugs like Bevacizumab, Sorafenib and Sunitinib. Drugs like Everolimus and Temsirolimus are mTOR inhibitors which works by blocking certain proteins that help tumor cells grow and divide. Immune checkpoint inhibitors like Nivolumab works by taking the brakes off immune system allowing it to attack cancer cells. The rising incidence of kidney cancer along with increasing adoption of targeted drug therapies over traditional therapies is propelling the growth of kidney cancer drug market.
The Global Kidney Cancer Drugs Market Demand is estimated to be valued at US$ 7.15 Bn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the kidney cancer drugs are Celanese Corporation, British Petroleum, Eastman Chemical Company, Jiangsu Sopo (Group) Co., Ltd., China Petroleum & Chemical Corporation (Sinopec), Lyondell Basell Industries, Saudi Basic Industries Corporation (SABIC), Mitsubishi Chemical Company, PetroChina Co. Ltd., PetroChina Co. Ltd., BASF SE. The rising prevalence of kidney cancer globally is anticipated to be a major driver for increasing demand of kidney cancer drugs. According to statistics, kidney cancer is among the top 10 cancers with highest incidence rate and nearly 403,000 new cases of kidney cancer were reported in 2020 worldwide. Technological advancements in targeted drug therapies has revolutionized treatment landscape of kidney cancer. Recent advances in development of immune checkpoint inhibitors and precision medicine approach for kidney cancer has improved patient outcomes.
Market Trends
Combination drug therapies for kidney cancer - Clinical trials evaluating efficacy and safety of combination of two or more targeted drugs or targeted drugs with immunotherapy drugs is a major trend. It is expected combination therapies can provide improved efficacy in treatment. Personalized medicine approach - Use of biomarkers and genomic profiling to understand molecular pathology of individual patient’s renal cancer and tailor treatment accordingly is gaining popularity. It has potential to improve outcomes through personalized treatment plans.
Market Opportunities
Immuno-oncology drugs - Immuno-oncology is emerging as mainstay of treatment for advanced kidney cancer. Approval of novel immuno-oncology drugs especially immune checkpoint inhibitors either as single or combination therapy presents lucrative opportunities. Drugs targeting new pathways - Ongoing research to identify new pathways and targets involved in kidney cancer development and progression could lead to discovery of novel drugs addressing unmet needs. This offers opportunities for pharmaceutical companies.
Impact of COVID-19 on Kidney Cancer Drugs Market Growth
The COVID-19 pandemic has significantly impacted the growth of the kidney cancer drugs market. During the initial lockdown phases imposed by various governments globally, there was a decline in the number of early-stage kidney cancer screenings and diagnoses. While healthcare systems were focused on tackling the ever-growing COVID-19 cases and prioritize resources for the same. This led to a fall in new prescriptions for kidney cancer drugs during 2020-2021. However, drug manufacturers ensured an uninterrupted supply of essential kidney cancer therapies throughout this period. With the resumption of regular healthcare activities post lockdowns, the market is recovering steadily. Despite short-term setbacks, the long-term outlook remains positive due to underlying demand drivers like aging population, lifestyle changes increasing risk of kidney cancers. Drug makers are also intensifying their R&D investments to develop newer targeted therapies and immunotherapies that help improve treatment outcomes.
North America Region Dominates Global Kidney Cancer Drugs Market in Terms of Value
The North America region dominates the global kidney cancer drugs market in terms of value. This is attributed to factors such as the rising prevalence of kidney cancer cases driven by obesity, high blood pressure in the region. Also, early diagnosis and availability of advanced targeted therapies have enabled effective treatment and management of the disease. The US represents a major market accounting for over 80% of the North American share. The region is expected to continue its leading position in the coming years considering ongoing clinical trials evaluating new therapeutics and strong reimbursement structure supporting access to expensive oncology care.
Asia Pacific Emerges as the Fastest Growing Region for Kidney Cancer Drugs Market
The Asia Pacific market is poised to grow at the fastest pace during the forecast period. This is owing to improving healthcare infrastructure, massive patient pool, and rising healthcare expenditures in emerging countries like China and India. Growing awareness among physicians and patients regarding early detection and modern treatment options is also supporting the regional market expansion. Furthermore, governments across various APAC nations have initiated several initiatives to reduce cancer burden, including favorable policies to boost the uptake of advanced cancer medications. Additionally, the presence of leading global drug manufacturers exploring business opportunities through partnerships with domestic players will likely accelerate kidney cancer drug sales in the Asia Pacific region.
For more insights, Read- https://www.trendingwebwire.com/kidney-cancer-drugs-market-growth-demand-and-overview/
